当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > The association between HSD17B1 Ser312Gly polymorphism and breast cancer risk: a meta-analysis including 31,053 subjects.

The association between HSD17B1 Ser312Gly polymorphism and breast cancer risk: a meta-analysis including 31,053 subjects.

Abstract：

:There are increasing evidences that HSD17B1 plays a significant role in the development of breast cancer. However, published data on the association between HSD17B1 Ser312Gly polymorphism and breast cancer risk are inconclusive. In order to derive a more precise estimation of this relationship, a meta-analysis including 9 studies with 31,053 subjects was performed in this study. Crude ORs with 95% CIs were used to assess the strength of association between HSD17B1 Ser312Gly polymorphism and breast cancer risk. The pooled ORs were performed for codominant model (Gly/Gly versus Ser/Ser, Gly/Ser versus Ser/Ser), dominant model (Gly/Gly + Gly/Ser versus Ser/Ser), and recessive model (Gly/Gly versus Gly/Ser + Ser/Ser), respectively. Overall, no significant associations were detected between HSD17B1 Ser312Gly polymorphism and breast cancer susceptibility. However, in the stratified analysis by ethnicity, significant associations were observed in Caucasians for Gly/Gly versus Ser/Ser (OR = 0.91; 95% CI 0.83-1.00), Gly/Ser versus Ser/Ser (OR = 0.92; 95% CI 0.85-0.99), and Gly/Gly + Gly/Ser versus Ser/Ser (OR = 0.92; 95% CI 0.86-0.98). In conclusion, this study suggests that HSD17B1 312Gly allele may be a protective factor for breast cancer development in Caucasians. However, large sample and representative population-based studies with homogeneous breast cancer patients and well-matched controls are warranted to confirm this finding.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Yao L,Cao LH,Qiu LX,Yu L

doi

10.1007/s10549-010-0784-4

subject

Has Abstract

pub_date

2010-09-01 00:00:00

pages

577-80

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

123

pub_type

杂志文章,meta分析

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Membrane proteases as potential diagnostic and therapeutic targets for breast malignancy.

    abstract：:Metastasizing cancer cells can invade the extracellular matrix using plasma membrane protrusions, termed invadopodia, that contact and dissolve the matrix. Various membrane associated proteases localized on the invadopodial membranes are responsible for the extracellular matrix degradation. Work from our laboratory sh...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00666155

    authors： Chen WT,Lee CC,Goldstein L,Bernier S,Liu CH,Lin CY,Yeh Y,Monsky WL,Kelly T,Dai M

    更新日期：1994-01-01 00:00:00

  • Alterations in cellular retinol metabolism contribute to differential retinoid responsiveness in normal human mammary epithelial cells versus breast cancer cells.

    abstract：:The present study was undertaken to compare ROH growth responsiveness between normal human mammary epithelial cells (HMECs), estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cells, and assess whether this responsiveness is correlated with differences in ROH metabolism, particularly RA synthes...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1014815112078

    authors： Hayden LJ,Satre MA

    更新日期：2002-03-01 00:00:00

  • The additionally glycosylated variant of human sex hormone-binding globulin (SHBG) is linked to estrogen-dependence of breast cancer.

    abstract：:Sex Hormone-Binding Globulin (SHBG), the plasma carrier for androgens and estradiol, inhibits the estradiol-induced proliferation of breast cancer cells through its membrane receptor, cAMP, and PKA. In addition, the SHBG membrane receptor is preferentially expressed in estrogen-dependent (ER+/PR+) breast cancers which...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006100929670

    authors： Becchis M,Frairia R,Ferrera P,Fazzari A,Ondei S,Alfarano A,Coluccia C,Biglia N,Sismondi P,Fortunati N

    更新日期：1999-03-01 00:00:00

  • Letrozole as primary medical therapy for locally advanced and large operable breast cancer.

    abstract：AIMS:To investigate the efficacy of letrozole 2.5 mg and 10 mg used as primary neoadjuvant therapy for patients with locally advanced and large operable breast cancer. PATIENTS AND METHODS:Twenty-four postmenopausal patients with locally advanced or large operable breast cancer were treated in two consecutive series w...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1010669403283

    authors： Dixon JM,Love CD,Bellamy CO,Cameron DA,Leonard RC,Smith H,Miller WR

    更新日期：2001-04-01 00:00:00

  • Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.

    abstract：PURPOSE:In the ACOSOG Z0011 trial, completing axillary lymph node dissection (cALND) did not benefit patients with T1-T2 cN0 early breast cancer and 1-2 positive sentinel lymph nodes (SLN) undergoing breast-conserving surgery (BCT). This paper reports cALND rates in the clinical routine for patients who had higher (T3-...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05876-z

    authors： Riedel F,Heil J,Feisst M,Moderow M,von Au A,Domschke C,Michel L,Schaefgen B,Golatta M,Hennigs A

    更新日期：2020-11-01 00:00:00

  • Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review.

    abstract：PURPOSE:Breast cancer is the most common cancer and leading cause of cancer death in women. Body composition parameters, especially those related to muscle, have become a growing focus of cancer research. In this review, we summarize the literature on breast cancer and muscle parameters as well as combine their outcome...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-019-05352-3

    authors： Aleixo GFP,Williams GR,Nyrop KA,Muss HB,Shachar SS

    更新日期：2019-10-01 00:00:00

  • Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode.

    abstract：:Irreversible electroporation (IRE) is a therapeutic technology for the ablation of soft tissues using electrodes to deliver intense but short electric pulses across a cell membrane, creating nanopores that lead to cell death. This phenomenon only affects the cell membrane, leaving the extracellular matrix and sensitiv...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-0803-5

    authors： Neal RE 2nd,Singh R,Hatcher HC,Kock ND,Torti SV,Davalos RV

    更新日期：2010-08-01 00:00:00

  • BRCA testing and outcomes in women with breast cancer.

    abstract：MAIN PURPOSE:Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carriers (BRCAwt) with breast cancer. RESEARCH QUESTION:The re...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-06038-x

    authors： Stenehjem DD,Telford C,Unni SK,Bauer H,Sainski A,Deka R,Schauerhamer MB,Ye X,Tak CR,Ma J,Dalvi TB,Gutierrez L,Kaye JA,Tyczynski JE,Brixner DI,Biskupiak JE

    更新日期：2021-01-03 00:00:00

  • Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death.

    abstract：PURPOSE:Complementary and alternative medicines (CAMS) are frequently used by patients with breast cancer and their use may be related to the presence of psychosocial distress. The objective of this study is to assess the presence of anxiety and depression in breast cancer patients who use CAM and assess how they perce...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-3779-1

    authors： Rakovitch E,Pignol JP,Chartier C,Ezer M,Verma S,Dranitsaris G,Clemons M

    更新日期：2005-03-01 00:00:00

  • A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer.

    abstract：:To date, three molecular markers (ER, PR, and CYP2D6) have been used in clinical setting to predict the benefit of the anti-estrogen tamoxifen therapy. Our aim was to validate new biomarker candidates predicting response to tamoxifen treatment in breast cancer by evaluating these in a meta-analysis of available transc...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-013-2622-y

    authors： Mihály Z,Kormos M,Lánczky A,Dank M,Budczies J,Szász MA,Győrffy B

    更新日期：2013-07-01 00:00:00

  • The 17q23 amplicon and breast cancer.

    abstract：:A novel region of amplification in breast tumors was recently identified on chromosome 17q23. Extensive mapping of the amplicon by Southern blotting and fluorescence in situ hybridization (FISH) in breast cancer cell lines determined that the amplicon can be up to 4 Mbp in size and may contain 50 genes. Copy number an...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1023081624133

    authors： Sinclair CS,Rowley M,Naderi A,Couch FJ

    更新日期：2003-04-01 00:00:00

  • Analysis of breast cancer in young women in the Department of Defense (DOD) database.

    abstract：PURPOSE:Breast tumors from young women under the age of 40 account for approximately 7% of cases and have a poor prognosis independent of established prognostic factors. We evaluated the patient population served by the Military Health System, where a disproportionate number of breast cancer cases in young women are se...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4615-8

    authors： Zimmer AS,Zhu K,Steeg PS,Wu A,Gatti-Mays ME,Soltani S,Perkins JG,Shao S,Brown D,Georg M,Hu H,Shriver CD,Lipkowitz S

    更新日期：2018-04-01 00:00:00

  • Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.

    abstract：:The present preclinical study was designed to evaluate a new combination therapy comprised of the aromatase inhibitor anastrozole (ANA) and the oral fluoropyrimidines, UFT and S-1 against the estrogen receptor (ER)-positive human breast cancer cell line MCF-7/Arom 14, which was stably transfected with the cDNA of huma...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1141-3

    authors： Nukatsuka M,Saito H,Nakagawa F,Abe M,Uchida J,Shibata J,Matsuo K,Noguchi S,Kiniwa M

    更新日期：2011-07-01 00:00:00

  • A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.

    abstract：:To determine whether capecitabine schedule adaptation improves the tolerability of capecitabine-paclitaxel combination therapy for metastatic breast cancer (MBC), patients with anthracycline-pretreated HER2-negative MBC were randomized to either arm A (21-day cycles: capecitabine 1,000 mg/m(2) twice daily, days 1-14; ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-011-1776-8

    authors： Lortholary A,Hardy-Bessard AC,Bachelot T,de Rauglaudre G,Alexandre J,Bourgeois H,Jaubert D,Paraiso D,Largillier R

    更新日期：2012-01-01 00:00:00

  • Pharmacology of aminoglutethimide: structure/activity relationships and receptor interactions.

    abstract：:The structure/activity relationships for inhibition of aromatase and cholesterol side-chain cleavage enzyme (CSCC) by aminoglutethimide and some of its analogues are reviewed. Although more effective against aromatase than CSCC, aminoglutethimide markedly inhibits both enzymes. Optimal competitive antagonism of aromat...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：

    authors： Nicholls PJ,Daly MJ,Smith HJ

    更新日期：1986-01-01 00:00:00

  • A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.

    abstract：:Lapatinib is approved in combination with capecitabine for treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) who have progressed on prior trastuzumab in the metastatic setting. Vinorelbine is an important chemotherapy option for MBC. We evaluated efficac...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-013-2828-z

    authors： Janni W,Sarosiek T,Karaszewska B,Pikiel J,Staroslawska E,Potemski P,Salat C,Brain E,Caglevic C,Briggs K,Desilvio M,Marini L,Papadimitriou C

    更新日期：2014-02-01 00:00:00

  • Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin.

    abstract：:Forty-one women with non-metastatic but locally advanced breast cancer were treated by modified radical or radical mastectomy, and were then randomized to receive one of two adjuvant chemotherapy regimens. Regimen A consisted of 6 months of cyclophosphamide, adriamycin, and fluorouracil (CAF) followed by 6 months of c...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF01806692

    authors： Casper ES,Guidera CA,Bosl GJ,Hakes TB,Kaufman RJ,Shurgot B,Kinne DW

    更新日期：1987-01-01 00:00:00

  • Effect of a multidiscipline mentor-based program, Be Resilient to Breast Cancer (BRBC), on female breast cancer survivors in mainland China-A randomized, controlled, theoretically-derived intervention trial.

    abstract：:To reduce the risk of adjustment problems for breast cancer patients in mainland China, we examined the efficacy of a multidiscipline mentor-based program, Be Resilient to Breast Cancer (BRBC), delivered after breast surgery to (a) increase protective factors of social support, hope for the future, etc.; (b) decrease ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-016-3881-1

    authors： Ye ZJ,Liang MZ,Qiu HZ,Liu ML,Hu GY,Zhu YF,Zeng Z,Zhao JJ,Quan XM

    更新日期：2016-08-01 00:00:00

  • Growth kinetics of four human breast carcinomas grown in nude mice.

    abstract：:The immune-deficient nude mouse with human tumor xenografts is an appropriate model system for performing detailed growth kinetic examinations. In the present study one estrogen and progesterone receptor-negative (T60) and three receptor-positive (Br-10, MCF-7, T61) human breast cancer xenografts in nude mice were inv...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01810740

    authors： Spang-Thomsen M,Rygaard K,Hansen L,Halvorsen AC,Vindeløv LL,Brünner N

    更新日期：1989-11-01 00:00:00

  • Inhibitory effects of Indole-3-carbinol on invasion and migration in human breast cancer cells.

    abstract：:Indole-3-carbinol (I3C) is a promising phytochemical agent in chemoprevention of breast cancer. Our present study is the first description of I3C that significantly inhibits the cell adhesion, spreading and invasion associated with an up-regulation of PTEN (a tumor suppressor gene) and E-cadherin (a regulator of cell-...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006495824158

    authors： Meng Q,Goldberg ID,Rosen EM,Fan S

    更新日期：2000-09-01 00:00:00

  • Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer.

    abstract：:In 1973, McGuire and Chamness (In: O'Malley BW and Means AR (ed) Receptors for Reproductive Hormones, Plenum Press) summarized their work on the estrogen receptor in animal and human breast tumors, and in so doing described a target for therapeutic intervention. At that time there were no clinically useful antiestroge...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00713399

    authors： Jordan VC

    更新日期：1995-01-01 00:00:00

  • Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).

    abstract：PURPOSE:We conducted an exploratory biomarker study from a phase II clinical trial of eribulin plus gemcitabine (EG) versus paclitaxel plus gemcitabine (PG) in HER2-negative metastatic breast cancer (BC) patients. METHODS:We performed targeted deep sequencing with a customized cancer gene panel and RNA expression assa...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05400-y

    authors： Kim JY,Lee E,Park K,Im SA,Sohn J,Lee KS,Chae YS,Kim JH,Kim TY,Jung KH,Park YH,Breast Cancer Committee of the Korean Cancer Study Group.

    更新日期：2019-11-01 00:00:00

  • Effectiveness of an additional individualized multi-component complementary medicine treatment on health-related quality of life in breast cancer patients: a pragmatic randomized trial.

    abstract：:The aim of this study was to evaluate the effectiveness of an additional, individualized, multi-component complementary medicine treatment offered to breast cancer patients at the Merano Hospital (South Tyrol) on health-related quality of life compared to patients receiving usual care only. A randomized pragmatic tria...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s10549-014-3249-3

    authors： Witt CM,Außerer O,Baier S,Heidegger H,Icke K,Mayr O,Mitterer M,Roll S,Spizzo G,Scherer A,Thuile C,Wieser A,Schützler L

    更新日期：2015-01-01 00:00:00

  • Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry.

    abstract：RATIONALE:Survival after loco-regional failure (LRF) of breast cancer was investigated at the population level. METHODS:Using the Stockholm cancer registry, 2698 patients diagnosed with LRF between 1980 and 2014 were identified and divided into three cohorts by year of LRF diagnosis. Post-relapse event-free survival (...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4936-2

    authors： Falato C,Taylor SK,Szulkin R,Nordblom A,Eriksson L,Sofiadis A,Fredriksson I,Hartman J,Bergh J,Foukakis T

    更新日期：2018-12-01 00:00:00

  • Tamoxifen-induced increases in cytoplasmic free Ca2+ levels in human breast cancer cells.

    abstract：:Tamoxifen has been shown to increase cytoplasmic free Ca2+ levels [Ca2+]i in renal tubular cells and bladder cancer cells, and to after Ca2+ signaling in MCF-7 breast cancer cells. The present study examined the effect of tamoxifen on [Ca2+], in ZR-75-1 human breast cancer cells using fura-2 as an indicator. Tamoxifen...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1013807731642

    authors： Chang HT,Huang JK,Wang JL,Cheng JS,Lee KC,Lo YK,Liu CP,Chou KJ,Chen WC,Su W,Law YP,Jan CR

    更新日期：2002-01-01 00:00:00

  • A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study.

    abstract：PURPOSE:Cardiac dysfunction risk associated with intravenous trastuzumab (H IV) treatment may differ in real-world practice versus randomized trials. We investigated cardiac events in patients with HER2-positive early breast cancer (EBC) treated with H IV as adjuvant therapy in routine practice. METHODS:The observatio...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-5058-6

    authors： Lidbrink E,Chmielowska E,Otremba B,Bouhlel A,Lauer S,Liste Hermoso M,Nüesch E,Shing M,Misra V

    更新日期：2019-02-01 00:00:00

  • The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.

    abstract：BACKGROUND:Cardiac toxicity from anthracyclines (ACH) can lead to therapy discontinuation, hospitalization or congestive heart failure (CHF). Since such risk may vary by patient, we developed and tested a risk-prediction tool for cardiac toxicity in metastatic breast cancer (MBC) patients receiving chemotherapy with do...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9803-5

    authors： Dranitsaris G,Rayson D,Vincent M,Chang J,Gelmon K,Sandor D,Reardon G

    更新日期：2008-02-01 00:00:00

  • Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy.

    abstract：:Sentinel lymph node (SLN) biopsy is rapidly emerging as an alternative to axillary lymph node dissection (ALND) for many female breast cancer patients. In contrast, ALND remains the standard of care for male breast cancer patients with similar tumors. We evaluated the results of SLN biopsy in male breast cancer patien...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1021173902253

    authors： Albo D,Ames FC,Hunt KK,Ross MI,Singletary SE,Kuerer HM

    更新日期：2003-01-01 00:00:00

  • The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.

    abstract：:Platinum agents such as cisplatin and carboplatin are DNA-damaging agents with activity in breast cancer (BC), particularly in the triple negative (TN) subgroup. The utility of platinum agents, in addition to standard neoadjuvant chemotherapy (NAC), is controversial. To assess the activity of platinum agents in patien...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-014-2876-z

    authors： Petrelli F,Coinu A,Borgonovo K,Cabiddu M,Ghilardi M,Lonati V,Barni S

    更新日期：2014-04-01 00:00:00

  • Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer.

    abstract：:This study analyzes the relationship between coxsackie-adenovirus receptor (CAR) expression (transmembrane and soluble isoforms) and hormone sensitivity in 95 breast cancers. Furthermore, prognostic significance of the expression of the various CAR isoforms was investigated. In addition, inducibility of CAR expression...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-0108-0

    authors： Auer D,Reimer D,Porto V,Fleischer M,Roessler J,Wiedemair A,Marth C,Müller-Holzner E,Daxenbichler G,Zeimet AG

    更新日期：2009-07-01 00:00:00